Advocates Eager To Learn More About Supreme Court Nominee Sotomayor's Abortion-Rights Views
Abortion-rights groups on Wednesday offered their support for Supreme Court nominee Judge Sonia Sotomayor but said that they were eager to learn more about her views on abortion rights, an issue on which she has made few major rulings in her time as a judge, the New York Times reports. According to the Times, groups on both sides of the abortion-rights debate tend to believe that Sotomayor would uphold Roe v. Wade because she was nominated by President Obama, who supports abortion rights. However, when asked on Tuesday if Obama questioned Sotomayor about her views on abortion rights before the nomination, White House spokesperson Robert Gibbs said that the president "did not ask that specifically." In addition, none of her rulings has directly dealt with the underlying issues of constitutional privacy that are the foundation for the Roe decision, according to the Times. The abortion-related cases Sotomayor has handled in the past have "turned on other legal issues," rather than privacy, and they have resulted in rulings in favor of abortion-right opponents, the Times reports. For example, in 2002, she wrote an opinion upholding the Bush administration"s "global gag rule" policy banning federal funding of international groups that offer abortion information or services. "The Supreme Court has made clear that the government is free to favor the antiabortion position over the pro-choice position and can do so with public funds," Sotomayor wrote in the opinion. In 2004, she said that antiabortion-rights protesters were permitted to sue police who they claimed used excessive force in stopping a demonstration at a clinic. Sotomayor also has ruled on several immigration cases related to people fighting deportation orders to China over its family planning policies, the Times reports. Because of the limited information on Sotomayor"s abortion-rights views, advocates have stressed that senators ask questions about her views during her confirmation hearing. NARAL Pro-Choice America President Nancy Keenan in a letter to supporters urged them to press senators to ask Sotomayor about privacy rights. Keenan wrote, "Discussion about [Roe] will -- and must -- be part of this nomination process. As you know, choice hangs in the balance on the Supreme Court as the last two major choice-related cases were decided by a 5-to-4 margin" (Savage, New York Times, 5/28). Nancy Northup, president of the Center for Reproductive Rights, said that she would be surprised if an Obama nominee did not support abortion rights but added that "other presidents have been surprised before" when their nominees" views did not align with their assumptions. Northup said that "no one has been able to give us an assurance" of Sotomayor"s views on abortion rights, adding that she would be "very concerned if the question is not asked and answered during the Senate hearings." Feminist Majority Foundation President Eleanor Smeal said, "What we know about [Sotomayor] we like, but I don"t know that answer on abortion rights" (Savage/Nicholas, Los Angeles Times, 5/28). The New York Times reports that more about Sotomayor"s views on abortion rights could come to light if a past writing on the subject surfaces, as was the case during Justice Samuel Alito"s confirmation process. Steven Waldman, editor in chief of beliefnet.com, said, "Everyone is just assuming that because Obama appointed her, she must be a die-hard pro-choice activist, but it"s really quite amazing how little we know about her views on abortion" (Savage, New York Times, 5/28). Thomas Goldstein, a leading appellate attorney and founder of scotusblog.com, said that the "fact that she hasn"t gone off on these sorts of questions" on contentious topics like abortion rights and gay marriage, "I think shows that honestly she"s not a dyed in the wool liberal." He added that there are issues on which Sotomayor could prove to be more conservative than retiring Justice David Souter (Lerer, Politico, 5/27).According to the Washington Post, many antiabortion-rights supporters are critic
Oncology
Pages: 1 [2]
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate And Treatment Failure In Patients With Chronic ITP
and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of June 7, 2009 and expressly disclaims any duty to update information contained in this news release. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modelled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others" regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labelling approved by the FDA for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labelling for the products, and not the information discussed in this news release. AmgenPages: 1 [2]